IKOS CIF’s Vertex Pharmaceuticals VRTX Stock Holding History

IKOS CIF’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-8,151	Closed	-$629K	–	222
2016 Q1	$629K	Buy	+8,151	New	+$737K	1.53%	19
2015 Q3	–	Sell	-2,379	Closed	-$295K	–	290
2015 Q2	$295K	Buy	2,379 +1,280	+116%	+$161K	0.97%	21
2015 Q1	$131K	Buy	+1,099	New	+$132K	0.3%	136

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

IKOS CIF's VRTX Position: Q2 2016 in Review

IKOS CIF sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 8,151 shares — an estimated $629K sold.

IKOS CIF first reported a position in VRTX in Q1 2015 and held it in 3 quarters. The position peaked at $629K in Q1 2016. 482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

IKOS CIF reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
IKOS CIF sold 8,151 Vertex Pharmaceuticals shares in Q2 2016, an estimated $629K.
IKOS CIF first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 3 quarters.
IKOS CIF's Vertex Pharmaceuticals position peaked at $629K in Q1 2016.
482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on IKOS CIF's 13F filing for Q2 2016, filed 12 Aug 2016.